WO2012062810A2 - Milieu de culture de cellules et procédé pour l'expression d'une protéine, lesdits milieu et procédé comprenant un inhibiteur de la pam - Google Patents

Milieu de culture de cellules et procédé pour l'expression d'une protéine, lesdits milieu et procédé comprenant un inhibiteur de la pam Download PDF

Info

Publication number
WO2012062810A2
WO2012062810A2 PCT/EP2011/069756 EP2011069756W WO2012062810A2 WO 2012062810 A2 WO2012062810 A2 WO 2012062810A2 EP 2011069756 W EP2011069756 W EP 2011069756W WO 2012062810 A2 WO2012062810 A2 WO 2012062810A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell culture
protein
culture medium
cho
cell
Prior art date
Application number
PCT/EP2011/069756
Other languages
English (en)
Other versions
WO2012062810A3 (fr
Inventor
Corinna Sonderegger
Julia Schmutzhard
Christine Heel
Thomas Stangler
Original Assignee
Sandoz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2816394A priority Critical patent/CA2816394A1/fr
Priority to PL11782121T priority patent/PL2638064T3/pl
Priority to CN201180053542XA priority patent/CN103298830A/zh
Priority to SG2013034871A priority patent/SG190182A1/en
Application filed by Sandoz Gmbh filed Critical Sandoz Gmbh
Priority to JP2013538186A priority patent/JP6298295B2/ja
Priority to US13/883,986 priority patent/US9062337B2/en
Priority to SI201131994T priority patent/SI2638064T1/sl
Priority to KR1020137013920A priority patent/KR101905204B1/ko
Priority to EP11782121.5A priority patent/EP2638064B1/fr
Priority to KR1020187019845A priority patent/KR101991215B1/ko
Priority to AU2011328166A priority patent/AU2011328166B2/en
Priority to DK11782121.5T priority patent/DK2638064T3/da
Publication of WO2012062810A2 publication Critical patent/WO2012062810A2/fr
Publication of WO2012062810A3 publication Critical patent/WO2012062810A3/fr
Priority to US14/721,679 priority patent/US10106828B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)

Abstract

La présente invention concerne un milieu de culture de cellules pour l'expression d'une protéine, milieu qui comprend un inhibiteur de la PAM, ou un équivalent physiologique de celui-ci, et un procédé de culture de cellules pour l'expression d'une protéine, procédé dans lequel un inhibiteur de la PAM, ou un équivalent physiologique de celui-ci, est utilisé.
PCT/EP2011/069756 2010-11-09 2011-11-09 Milieu de culture de cellules et procédé pour l'expression d'une protéine, lesdits milieu et procédé comprenant un inhibiteur de la pam WO2012062810A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US13/883,986 US9062337B2 (en) 2010-11-09 2011-11-09 Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
CN201180053542XA CN103298830A (zh) 2010-11-09 2011-11-09 用于蛋白表达的细胞培养基和方法，所述培养基和方法包括一种pam抑制剂
SG2013034871A SG190182A1 (en) 2010-11-09 2011-11-09 Cell culture medium and process for protein expression, said medium and process comprising a pam inhibitor
KR1020137013920A KR101905204B1 (ko) 2010-11-09 2011-11-09 Pam 억제제를 포함하는, 단백질 발현을 위한 세포 배지 및 배양 방법
JP2013538186A JP6298295B2 (ja) 2010-11-09 2011-11-09 タンパク質発現のための細胞培養培地及びプロセス、ｐａｍインヒビターを含む前記培地及びプロセス
PL11782121T PL2638064T3 (pl) 2010-11-09 2011-11-09 Pożywka do hodowli komórkowej i sposób ekspresji białka, przy czym wymieniona pożywka i sposób obejmują inhibitory pam
SI201131994T SI2638064T1 (sl) 2010-11-09 2011-11-09 Celični gojitveni medij in postopek za izražanje proteina, pri čemer medij in postopek obsegata inhibitor PAM
CA2816394A CA2816394A1 (fr) 2010-11-09 2011-11-09 Milieu de culture de cellules et procede pour l'expression d'une proteine, lesdits milieu et procede comprenant un inhibiteur de la pam
EP11782121.5A EP2638064B1 (fr) 2010-11-09 2011-11-09 Milieu de culture de cellules et procédé pour l'expression d'une protéine, lesdits milieu et procédé comprenant un inhibiteur de la pam
KR1020187019845A KR101991215B1 (ko) 2010-11-09 2011-11-09 Pam 억제제를 포함하는, 단백질 발현을 위한 세포 배지 및 배양 방법
AU2011328166A AU2011328166B2 (en) 2010-11-09 2011-11-09 Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
DK11782121.5T DK2638064T3 (da) 2010-11-09 2011-11-09 Celledyrkningsmedie og fremgangsmåde til proteinekspression, hvilket medie og hvilken fremgangsmåde omfatter en PAM inhibitor
US14/721,679 US10106828B2 (en) 2010-11-09 2015-05-26 Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190532.1 2010-11-09
EP10190532A EP2450375A1 (fr) 2010-11-09 2010-11-09 Milieu de culture cellulaire et procédé pour l'expression de protéines, ledit milieu et ledit procédé comprenant un inhibiteur de PAM

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/883,986 A-371-Of-International US9062337B2 (en) 2010-11-09 2011-11-09 Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
US14/721,679 Continuation US10106828B2 (en) 2010-11-09 2015-05-26 Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor

Publications (2)

Publication Number Publication Date
WO2012062810A2 true WO2012062810A2 (fr) 2012-05-18
WO2012062810A3 WO2012062810A3 (fr) 2012-07-05

Family

ID=43795181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/069756 WO2012062810A2 (fr) 2010-11-09 2011-11-09 Milieu de culture de cellules et procédé pour l'expression d'une protéine, lesdits milieu et procédé comprenant un inhibiteur de la pam

Country Status (13)

Country Link
US (2) US9062337B2 (fr)
EP (2) EP2450375A1 (fr)
JP (2) JP6298295B2 (fr)
KR (2) KR101991215B1 (fr)
CN (2) CN103298830A (fr)
AU (1) AU2011328166B2 (fr)
CA (1) CA2816394A1 (fr)
DK (1) DK2638064T3 (fr)
HU (1) HUE055573T2 (fr)
PL (1) PL2638064T3 (fr)
SG (2) SG10201602507UA (fr)
SI (1) SI2638064T1 (fr)
WO (1) WO2012062810A2 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156458A1 (fr) * 2012-04-16 2013-10-24 Lek Pharmaceuticals D.D. Réduction de la formation d'acides aminés amidés dans des lignées cellulaires pour l'extraction protéique
US8895709B2 (en) 2008-10-20 2014-11-25 Abbvie Inc. Isolation and purification of antibodies using protein A affinity chromatography
US8906646B2 (en) 2006-09-13 2014-12-09 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9062337B2 (en) 2010-11-09 2015-06-23 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9109010B2 (en) 2008-10-20 2015-08-18 Abbvie Inc. Viral inactivation during purification of antibodies cross reference to related applications
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US10196601B2 (en) 2013-08-20 2019-02-05 Lek Pharmaceuticals D.D. Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
WO2020201296A1 (fr) 2019-04-01 2020-10-08 The Automation Partnership (Cambridge) Ltd. Procédé de fonctionnement pour un système de culture cellulaire

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054420T2 (hu) 2016-10-17 2021-09-28 Enzene Biosciences Ltd Folyamatos eljárás terápiás fehérje heterogenitásának csökkentésére

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221361A3 (fr) * 1996-08-30 2011-02-09 Life Technologies Corporation Méthode de production d'un polypeptide in vitro dans une cellule de mammifère dans un milieu de culture sans sérum and sans protéines
JP2008529495A (ja) * 2005-02-04 2008-08-07 グラクソ グループ リミテッド 異種ポリペプチド発現の最適化
US20080227134A9 (en) * 2005-09-16 2008-09-18 Unigene Laboratories Inc. Glyoxylate assays and their use of inden tifying natural amidated compounds
BRPI0617491B1 (pt) * 2005-10-18 2021-04-27 Ajinomoto Co., Inc Processo para produção de ácido succínico
PE20130398A1 (es) 2010-07-15 2013-04-10 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo
EP2450375A1 (fr) 2010-11-09 2012-05-09 Sandoz Gmbh Milieu de culture cellulaire et procédé pour l'expression de protéines, ledit milieu et ledit procédé comprenant un inhibiteur de PAM

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAUER ET AL.: "Anti-Inflammatory Effects of 4-Phenyl-3-butenoic Acid and 5-(Acetylamino)-4-oxo-6-phenyl-2-hexenoic Acid Methyl Ester, Potential Inhibitors of Neuropeptide Bioactivation", J PHARMACOL EXP THER, vol. 320, March 2007 (2007-03-01), pages 1171 - 1177
CHEW, G: "Substrate-Based Inhibitors of Peptidylglycine Amidating Monooxygenase (PAM) as Anti-Proliferative Drugs for Cancer", MASTER THESIS, 2003

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284371B2 (en) 2006-09-13 2016-03-15 Abbvie Inc. Methods of producing adalimumab
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US9090867B2 (en) 2006-09-13 2015-07-28 Abbvie Inc. Fed-batch method of making anti-TNF-alpha antibody
US9234032B2 (en) 2006-09-13 2016-01-12 Abbvie Inc. Fed-batch methods for producing adalimumab
US9073988B2 (en) 2006-09-13 2015-07-07 Abbvie Inc. Fed batch method of making anti-TNF-alpha antibodies
US8906646B2 (en) 2006-09-13 2014-12-09 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US10119118B2 (en) 2006-09-13 2018-11-06 Abbvie Inc. Modified serum-free cell culture medium
US9018361B2 (en) 2008-10-20 2015-04-28 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
US9109010B2 (en) 2008-10-20 2015-08-18 Abbvie Inc. Viral inactivation during purification of antibodies cross reference to related applications
US8895709B2 (en) 2008-10-20 2014-11-25 Abbvie Inc. Isolation and purification of antibodies using protein A affinity chromatography
US10106828B2 (en) 2010-11-09 2018-10-23 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
US9062337B2 (en) 2010-11-09 2015-06-23 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505834B2 (en) 2011-04-27 2016-11-29 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9255143B2 (en) 2011-04-27 2016-02-09 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9090688B2 (en) 2011-04-27 2015-07-28 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP2015519884A (ja) * 2012-04-16 2015-07-16 レツク・フアーマシユーテイカルズ・デー・デー タンパク質発現のための細胞株におけるアミド化アミノ酸形成の減少
US9637769B2 (en) 2012-04-16 2017-05-02 Lek Pharmaceuticals D.D. Reduction of formation of amidated amino acids in cell lines for protein expression
WO2013156458A1 (fr) * 2012-04-16 2013-10-24 Lek Pharmaceuticals D.D. Réduction de la formation d'acides aminés amidés dans des lignées cellulaires pour l'extraction protéique
AU2013248356B2 (en) * 2012-04-16 2017-03-16 Lek Pharmaceuticals D.D. Reduction of formation of amidated amino acids in cell lines for protein expression
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9359434B2 (en) 2012-04-20 2016-06-07 Abbvie, Inc. Cell culture methods to reduce acidic species
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9957318B2 (en) 2012-04-20 2018-05-01 Abbvie Inc. Protein purification methods to reduce acidic species
US9346879B2 (en) 2012-04-20 2016-05-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9290568B2 (en) 2012-09-02 2016-03-22 Abbvie, Inc. Methods to control protein heterogeneity
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
US10196601B2 (en) 2013-08-20 2019-02-05 Lek Pharmaceuticals D.D. Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9266949B2 (en) 2013-10-18 2016-02-23 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9200069B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9200070B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9315574B2 (en) 2013-10-18 2016-04-19 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
WO2020201296A1 (fr) 2019-04-01 2020-10-08 The Automation Partnership (Cambridge) Ltd. Procédé de fonctionnement pour un système de culture cellulaire

Also Published As

Publication number Publication date
US9062337B2 (en) 2015-06-23
CN103298830A (zh) 2013-09-11
HUE055573T2 (hu) 2021-12-28
JP2013541963A (ja) 2013-11-21
CN107629995A (zh) 2018-01-26
EP2638064A2 (fr) 2013-09-18
KR20180082643A (ko) 2018-07-18
AU2011328166A1 (en) 2013-05-30
KR101991215B1 (ko) 2019-09-30
SG10201602507UA (en) 2016-05-30
JP2017035084A (ja) 2017-02-16
US10106828B2 (en) 2018-10-23
CA2816394A1 (fr) 2012-05-18
US20130337506A1 (en) 2013-12-19
KR101905204B1 (ko) 2018-10-05
AU2011328166B2 (en) 2017-02-23
SI2638064T1 (sl) 2021-11-30
WO2012062810A3 (fr) 2012-07-05
DK2638064T3 (da) 2021-10-04
JP6298295B2 (ja) 2018-03-20
PL2638064T3 (pl) 2021-12-20
US20150267238A1 (en) 2015-09-24
SG190182A1 (en) 2013-06-28
EP2638064B1 (fr) 2021-07-21
KR20130131355A (ko) 2013-12-03
EP2450375A1 (fr) 2012-05-09

Similar Documents

Publication Publication Date Title
US10106828B2 (en) Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
US9388447B2 (en) Method for culturing mammalian cells to improve recombinant protein production
US11319568B2 (en) Methods for increasing mannose content of recombinant proteins
AU2020239681B2 (en) Overexpression Of N-Glycosylation Pathway Regulators To Modulate Glycosylation Of Recombinant Proteins
SG187198A1 (en) Dipeptides to enhance yield and viability from cell cultures
KR20160036612A (ko) 폴리펩티드의 α-아미드화 및/또는 C-말단 아미노산 분열의 제어를 위한 세포 배양 매질 및 방법
US10106829B2 (en) Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11782121

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2816394

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013538186

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13883986

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011782121

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011328166

Country of ref document: AU

Date of ref document: 20111109

Kind code of ref document: A

Ref document number: 20137013920

Country of ref document: KR

Kind code of ref document: A